STOCKHOLM - April 29, 2026 - Inify Laboratories, a unique laboratory service
that provides cancer diagnostics within pathology, today announces significant
progress in its UK market entry and continued sales growth in Sweden during the
first quarter.
Sales increased compared to the same period last year, with the company's
Swedish subsidiary delivering positive results for the sixth consecutive
quarter. At the same time, Inify has made important progress in the UK through
advancing discussions with the NHS at both national and hospital levels.
"We are very encouraged by the progress we are making with the NHS," said
Fredrik Palm, CEO of Inify Laboratories. "Entering the UK public healthcare
system is a complex process, but we are now engaged in concrete contract
discussions, which is a clear sign that our offering is gaining traction."
Advancing towards UK operational start
During the quarter, Inify initiated contract discussions with NHS stakeholders
regarding staged, funded evaluation projects. These evaluations are designed to
assess performance within existing care pathways before gradually transitioning
to Inify's diagnostic services.
The company expects to begin receiving its first patient samples from the UK in
June. The laboratory in the UK is fully equipped and technically verified, and
regulatory approval for routine clinical operations is anticipated in the second
quarter.
"While the timeline is slightly later than originally planned, it aligns well
with when we expect to start receiving patient samples," added Palm. "Each step
in this process strengthens our position and supports the path to broader
implementation."
Continued growth in Sweden
In Sweden, Inify continues to demonstrate strong operational and commercial
momentum. The company's laboratory has now achieved six consecutive quarters of
positive results, supported by increasing demand for its prostate cancer
diagnostics services.
Growth forward is primarily expected to come from the public healthcare sector,
where Inify recently began receiving patient samples as part of a new regional
evaluation project. The company also reports several ongoing dialogues with
additional regions.
"Our Swedish operations clearly demonstrate the value we bring," said Palm. "We
are seeing both increased volumes of samples in the laboratory and tangible
improvements for healthcare providers, including shorter turnaround times and
enhanced workflow."
Official statistics shows that regions that are sending their patient samples to
Inify has reduced the waiting times for results to patient by several weeks,
while also enabling new, more efficient ways of working across the patient
pathway.
In addition to its prostate cancer diagnostics offering, Inify recently received
extended ISO 15189 accreditation for gastrointestinal diagnostics, opening new
avenues for growth with both private and public healthcare providers.
"Next major step not a question of if - but when"
Following a successful share issue completed in March, Inify has strengthened
its financial position to support continued expansion, particularly in the UK
market.
"We are in a phase where persistence and execution are key," Palm concluded.
"The demand for efficient, higher-quality diagnostics is clear. With a strong
foundation in Sweden and meaningful progress in the UK, it is not a question of
if - but when - we take the next major step in our growth journey."
For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com
###
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)